nach oben

Advances in Therapy

Erschienen in:

28.05.2019 | Original Research

Intravitreal Dexamethasone Implant for Treatment of Sarcoidosis-Related Uveitis

verfasst von: Mirinae Kim, Seong Ah Kim, Wookyung Park, Rae Young Kim, Young-Hoon Park

Erschienen in: Advances in Therapy | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the efficacy and safety of intravitreal dexamethasone implant injection in the management of sarcoidosis-related uveitis.

Methods

A retrospective analysis was performed of the efficacy and safety of intravitreal dexamethasone implant injection for indications such as intractable vitritis, vasculitis, or cystoid macular edema.

Results

This study comprised 20 patients with sarcoidosis-related uveitis. A single injection was performed in 13 eyes (65%) and 35% required more than 2 injections during the follow-up period [median 16.5 months (range 6–32)]. The best-corrected visual acuity showed significant improvement at 1 month (P = 0.004) and 3 months (P = 0.001), but there was no significance at 6 months after implant injection (P = 0.186). One month after treatment, the central macular thickness decreased to 278.95 ± 52.20 μm (P = 0.023). It further decreased to 274.70 ± 55.88 μm at 3 months (P = 0.027), but there was no significance at 6 months (280.65 ± 64.48 μm, P = 0.074).The anterior chamber cell grade (P = 0.003) and vitreous haze (P = 0.001) were significantly decreased for up to 6 months after a single implant injection. The most common ocular complication was worsening of cataracts during the first 6 months.

Conclusion

Intravitreal dexamethasone implant injection is efficacious in reducing anterior chamber inflammation, vitreous haze, and cystoid macular edema in patients with sarcoidosis-related uveitis. Considering that sarcoidosis shows a chronic course of disease in a significant proportion of cases, intravitreal dexamethasone implant injection is a possible option to relieve intraocular inflammation.

Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336:1224–34. https://doi.org/10.1056/nejm199704243361706.CrossRefPubMed

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee. 1999. Am J Respir Crit Care Med 160: 736–755. https://doi.org/10.1164/ajrccm.160.2.ats4-99.

Herbort CP, Rao NA, Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009;17:160–9. https://doi.org/10.1080/09273940902818861.CrossRefPubMed

Jamilloux Y, Kodjikian L, Broussolle C, Seve P. Sarcoidosis and uveitis. Autoimmun Rev. 2014;13:840–9. https://doi.org/10.1016/j.autrev.2014.04.001.CrossRefPubMed

Ma SP, Rogers SL, Hall AJ, Hodgson L, Brennan J, Stawell RJ, Lim LL. Sarcoidosis-related uveitis: clinical presentation, disease course, and rates of systemic disease progression after uveitis diagnosis. Am J Ophthalmol. 2019;198:30–6. https://doi.org/10.1016/j.ajo.2018.09.013.CrossRefPubMed

Rothova A, Alberts C, Glasius E, Kijlstra A, Buitenhuis HJ, Breebaart AC. Risk factors for ocular sarcoidosis. Doc Ophthalmol. 1989;72:287–96.CrossRefPubMed

Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, McLennan G, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki B, Weinberger SE, Terrin ML, Knatterud GL, Cherniak R. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885–9. https://doi.org/10.1164/ajrccm.164.10.2104046.CrossRefPubMed

Matsou A, Tsaousis KT. Management of chronic ocular sarcoidosis: challenges and solutions. Clin Ophthalmol. 2018;12:519–32. https://doi.org/10.2147/opth.s128949.CrossRefPubMedPubMedCentral

Riancho-Zarrabeitia L, Calvo-Rio V, Blanco R, Mesquida M, Adan AM, Herreras JM, Aparicio A, Peiteado-Lopez D, Cordero-Coma M, Garcia Serrano JL, Ortego-Centeno N, Maiz O, Blanco A, Sanchez-Burson J, Gonzalez-Suarez S, Fonollosa A, Santos-Gomez M, Gonzalez-Vela C, Loricera J, Pina T, Gonzalez-Gay MA. Anti-TNF-alpha therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients. Semin Arthritis Rheum. 2015;45:361–8. https://doi.org/10.1016/j.semarthrit.2015.05.010.CrossRefPubMed

10.

Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–65. https://doi.org/10.1056/NEJMra071714.CrossRefPubMed

11.

Cottin V. Update on bioagent therapy in sarcoidosis. F1000 medicine reports, 2, 13. 2010. https://doi.org/10.3410/m2-13. Accessed 8 Aug 2019.

12.

Myung JS, Aaker GD, Kiss S. Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant. Clin Ophthalmol. 2010;4:1423–6. https://doi.org/10.2147/opth.s15696.CrossRefPubMedPubMedCentral

13.

Zarranz-Ventura J, Carreno E, Johnston RL, Mohammed Q, Ross AH, Barker C, Fonollosa A, Artaraz J, Pelegrin L, Adan A, Lee RW, Dick AD, Sallam A. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. 2014;158:1136–1145.e1135. https://doi.org/10.1016/j.ajo.2014.09.003.CrossRefPubMed

14.

Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–16.CrossRefPubMed

15.

Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li X-Y, Cui H, Whitcup SM, Group OHS. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–53. https://doi.org/10.1001/archophthalmol.2010.339.CrossRefPubMed

16.

Stanbury RM, Graham EM. Systemic corticosteroid therapy–side effects and their management. Br J Ophthalmol. 1998;82:704–8.CrossRefPubMedPubMedCentral

17.

Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33:289–94.CrossRef

18.

Tomkins-Netzer O, Taylor SR, Bar A, Lula A, Yaganti S, Talat L, Lightman S. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. 2014;121:1649–54. https://doi.org/10.1016/j.ophtha.2014.02.003.CrossRefPubMed

19.

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134–1146.e1133. https://doi.org/10.1016/j.ophtha.2010.03.032.CrossRefPubMed

20.

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Li J. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453–60. https://doi.org/10.1016/j.ophtha.2011.05.014.CrossRefPubMed

21.

Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A. Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye (Lond). 2013;27:65–71. https://doi.org/10.1038/eye.2012.226.CrossRef

22.

Calvo P, Ferreras A, Al Adel F, Dangboon W, Brent MH. Effect of an intravitreal dexamethasone implant on diabetic macular edema after cataract surgery. Retina. 2018;38:490–6. https://doi.org/10.1097/iae.0000000000001552.CrossRefPubMed

23.

Malcles A, Dot C, Voirin N, Agard E, Vie AL, Bellocq D, Denis P, Kodjikian L. Real-life study in diabetic macular edema treated with dexamethasone implant: the Reldex Study. Retina. 2017;37:753–60. https://doi.org/10.1097/iae.0000000000001234.CrossRefPubMed

24.

Malcles A, Dot C, Voirin N, Vie AL, Agard E, Bellocq D, Denis P, Kodjikian L, Safety of Intravitreal Dexamethasone Implant (Ozurdex): The SAFODEX study. Incidence and risk factors of ocular hypertension. Retina. 2017;37:1352–9. https://doi.org/10.1097/iae.0000000000001369.CrossRefPubMed

25.

Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, Baath J, Buys YM. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013;58:291–310. https://doi.org/10.1016/j.survophthal.2012.08.003.CrossRefPubMed

Titel: Intravitreal Dexamethasone Implant for Treatment of Sarcoidosis-Related Uveitis
verfasst von: Mirinae Kim
Seong Ah Kim
Wookyung Park
Rae Young Kim
Young-Hoon Park
Publikationsdatum: 28.05.2019
Verlag: Springer Healthcare
Erschienen in: Advances in Therapy / Ausgabe 8/2019
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-019-00989-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

Correction to: Immunogenic Yeast-Based Fermentation Product Reduces Allergic Rhinitis-Induced Nasal Congestion: A Randomized, Double-Blind, Placebo-Controlled Trial

Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer

Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis

Sleep Quality and Congestion with Breathe Right Nasal Strips: Two Randomized Controlled Trials

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14

Development of a Patient-Reported Outcome Measure for Chronic Hypoparathyroidism